Cyrus Rustam Mehta, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sample Size | 17 | 2017 | 844 | 2.600 |
Why?
|
| Research Design | 21 | 2017 | 5979 | 2.040 |
Why?
|
| Data Interpretation, Statistical | 14 | 2014 | 2714 | 1.780 |
Why?
|
| Clinical Trials as Topic | 19 | 2017 | 7901 | 1.660 |
Why?
|
| Uracil | 10 | 2018 | 164 | 1.270 |
Why?
|
| Confidence Intervals | 9 | 2016 | 2970 | 1.080 |
Why?
|
| Models, Statistical | 19 | 2017 | 5100 | 1.060 |
Why?
|
| Biometry | 11 | 2017 | 558 | 0.890 |
Why?
|
| Clinical Trials, Phase III as Topic | 4 | 2016 | 839 | 0.810 |
Why?
|
| Piperidines | 10 | 2018 | 1602 | 0.760 |
Why?
|
| Randomized Controlled Trials as Topic | 7 | 2014 | 9941 | 0.650 |
Why?
|
| Acute Coronary Syndrome | 10 | 2018 | 2337 | 0.510 |
Why?
|
| Iatrogenic Disease | 1 | 2018 | 545 | 0.500 |
Why?
|
| Endpoint Determination | 5 | 2017 | 600 | 0.470 |
Why?
|
| Markov Chains | 2 | 2014 | 969 | 0.430 |
Why?
|
| Femur | 1 | 2018 | 1297 | 0.410 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 5 | 2018 | 292 | 0.400 |
Why?
|
| Epidemiologic Research Design | 2 | 2010 | 367 | 0.360 |
Why?
|
| Computer Simulation | 10 | 2017 | 6191 | 0.340 |
Why?
|
| Hypoglycemic Agents | 9 | 2017 | 2866 | 0.300 |
Why?
|
| Multicenter Studies as Topic | 2 | 2011 | 1661 | 0.300 |
Why?
|
| Arthroplasty, Replacement, Hip | 1 | 2018 | 1461 | 0.300 |
Why?
|
| Diabetes Mellitus, Type 2 | 10 | 2018 | 11695 | 0.260 |
Why?
|
| Algorithms | 11 | 2017 | 13853 | 0.260 |
Why?
|
| Diabetic Cardiomyopathies | 2 | 2017 | 96 | 0.250 |
Why?
|
| Neurotoxins | 1 | 2004 | 237 | 0.220 |
Why?
|
| Diabetic Angiopathies | 3 | 2017 | 820 | 0.200 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2009 | 1873 | 0.190 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2016 | 627 | 0.190 |
Why?
|
| Standard of Care | 3 | 2017 | 562 | 0.170 |
Why?
|
| Gatekeeping | 1 | 2017 | 45 | 0.150 |
Why?
|
| Likelihood Functions | 3 | 2001 | 1003 | 0.140 |
Why?
|
| Monte Carlo Method | 3 | 2013 | 1254 | 0.130 |
Why?
|
| Myocardial Revascularization | 2 | 2017 | 841 | 0.130 |
Why?
|
| Humans | 48 | 2018 | 742088 | 0.130 |
Why?
|
| Naphthyridines | 1 | 2015 | 118 | 0.130 |
Why?
|
| Acetabulum | 1 | 2018 | 525 | 0.120 |
Why?
|
| Probability | 5 | 1994 | 2502 | 0.120 |
Why?
|
| Glucosides | 1 | 2017 | 446 | 0.120 |
Why?
|
| Cytarabine | 1 | 2015 | 684 | 0.110 |
Why?
|
| Propranolol | 1 | 2015 | 502 | 0.110 |
Why?
|
| Deep Brain Stimulation | 2 | 2013 | 746 | 0.110 |
Why?
|
| Troponin I | 1 | 2017 | 619 | 0.110 |
Why?
|
| Skin Diseases, Bacterial | 1 | 2013 | 66 | 0.110 |
Why?
|
| Angina, Unstable | 2 | 2015 | 926 | 0.110 |
Why?
|
| Government Regulation | 1 | 2016 | 522 | 0.100 |
Why?
|
| Double-Blind Method | 8 | 2017 | 12017 | 0.100 |
Why?
|
| Hip Joint | 1 | 2018 | 1002 | 0.100 |
Why?
|
| Benzhydryl Compounds | 1 | 2017 | 840 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2016 | 10943 | 0.090 |
Why?
|
| Hemangioma | 1 | 2015 | 737 | 0.090 |
Why?
|
| Hypoglycemia | 1 | 2017 | 859 | 0.090 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2016 | 1517 | 0.090 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2015 | 1239 | 0.080 |
Why?
|
| Myocardial Infarction | 5 | 2018 | 11690 | 0.080 |
Why?
|
| Cholesterol, LDL | 1 | 2017 | 2354 | 0.080 |
Why?
|
| Hyperglycemia | 1 | 2017 | 1368 | 0.080 |
Why?
|
| Thiazoles | 1 | 2015 | 1484 | 0.080 |
Why?
|
| Statistics, Nonparametric | 1 | 1994 | 2885 | 0.080 |
Why?
|
| Survival Analysis | 3 | 2014 | 10248 | 0.070 |
Why?
|
| Treatment Outcome | 11 | 2018 | 62966 | 0.070 |
Why?
|
| Parkinson Disease | 2 | 2013 | 2774 | 0.070 |
Why?
|
| Software | 2 | 2006 | 4434 | 0.070 |
Why?
|
| Cardiovascular Diseases | 4 | 2017 | 15108 | 0.070 |
Why?
|
| C-Reactive Protein | 1 | 2017 | 3766 | 0.070 |
Why?
|
| Mortality | 1 | 2017 | 2857 | 0.070 |
Why?
|
| Logistic Models | 2 | 2001 | 13403 | 0.060 |
Why?
|
| Patient Selection | 2 | 2014 | 4214 | 0.060 |
Why?
|
| Tetrachloroethylene | 1 | 2004 | 6 | 0.060 |
Why?
|
| Therapeutic Equivalency | 1 | 1984 | 145 | 0.060 |
Why?
|
| Heart Failure | 3 | 2017 | 10856 | 0.060 |
Why?
|
| Drug Design | 1 | 2009 | 1078 | 0.060 |
Why?
|
| Proportional Hazards Models | 3 | 2016 | 12344 | 0.060 |
Why?
|
| United States Food and Drug Administration | 1 | 2010 | 1581 | 0.050 |
Why?
|
| Mathematics | 2 | 1994 | 727 | 0.050 |
Why?
|
| Aged | 11 | 2018 | 162944 | 0.050 |
Why?
|
| Biological Assay | 1 | 2004 | 652 | 0.050 |
Why?
|
| Drug Therapy | 2 | 2013 | 497 | 0.050 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2015 | 3497 | 0.040 |
Why?
|
| Stroke | 3 | 2018 | 9963 | 0.040 |
Why?
|
| Drug Administration Schedule | 3 | 2016 | 4929 | 0.040 |
Why?
|
| Sodium-Glucose Transporter 2 | 1 | 2017 | 85 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2015 | 9185 | 0.040 |
Why?
|
| Drug Therapy, Combination | 3 | 2017 | 6483 | 0.040 |
Why?
|
| Middle Aged | 12 | 2018 | 213127 | 0.040 |
Why?
|
| Female | 19 | 2018 | 379592 | 0.040 |
Why?
|
| Classification | 1 | 1996 | 129 | 0.030 |
Why?
|
| Schizophrenia | 2 | 2010 | 6874 | 0.030 |
Why?
|
| Risk Assessment | 3 | 2016 | 23320 | 0.030 |
Why?
|
| Genitalia | 1 | 1996 | 111 | 0.030 |
Why?
|
| CD4-CD8 Ratio | 1 | 1995 | 112 | 0.030 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2014 | 5171 | 0.030 |
Why?
|
| Male | 15 | 2018 | 349538 | 0.030 |
Why?
|
| Disease-Free Survival | 2 | 2015 | 6891 | 0.030 |
Why?
|
| Accident Prevention | 1 | 1994 | 78 | 0.030 |
Why?
|
| Carotenoids | 1 | 1996 | 624 | 0.030 |
Why?
|
| Obstetric Labor Complications | 1 | 1995 | 238 | 0.030 |
Why?
|
| Survival Rate | 2 | 2018 | 12773 | 0.030 |
Why?
|
| Sodium | 1 | 2017 | 1627 | 0.030 |
Why?
|
| Hospitalization | 3 | 2016 | 10232 | 0.030 |
Why?
|
| Lung Neoplasms | 3 | 2014 | 13019 | 0.030 |
Why?
|
| Selection Bias | 1 | 1994 | 369 | 0.030 |
Why?
|
| Quality of Life | 1 | 2013 | 12730 | 0.030 |
Why?
|
| Mouth Diseases | 1 | 1994 | 239 | 0.020 |
Why?
|
| Drug Resistance | 1 | 2017 | 1608 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2017 | 1520 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 1995 | 2030 | 0.020 |
Why?
|
| Osteosarcoma | 1 | 1995 | 880 | 0.020 |
Why?
|
| Remission Induction | 1 | 2015 | 2384 | 0.020 |
Why?
|
| Incidence | 2 | 2018 | 20928 | 0.020 |
Why?
|
| United States | 3 | 2018 | 69693 | 0.020 |
Why?
|
| Macular Degeneration | 1 | 1996 | 980 | 0.020 |
Why?
|
| Reference Values | 1 | 2016 | 4982 | 0.020 |
Why?
|
| Linear Models | 2 | 2003 | 5948 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 2 | 2013 | 5385 | 0.020 |
Why?
|
| Hypotension | 1 | 2015 | 880 | 0.020 |
Why?
|
| Analgesics | 1 | 1995 | 1037 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 2013 | 1459 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2015 | 3913 | 0.020 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2015 | 1573 | 0.020 |
Why?
|
| Pregnancy | 3 | 2001 | 29087 | 0.020 |
Why?
|
| Time Factors | 1 | 2008 | 40054 | 0.020 |
Why?
|
| Arrhythmias, Cardiac | 1 | 1995 | 2267 | 0.020 |
Why?
|
| Efficiency, Organizational | 1 | 2009 | 695 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 8621 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 6534 | 0.020 |
Why?
|
| Risk | 1 | 2016 | 9679 | 0.010 |
Why?
|
| Alcohol Drinking | 1 | 1996 | 3957 | 0.010 |
Why?
|
| Drug Industry | 1 | 2009 | 744 | 0.010 |
Why?
|
| Epidemiologic Methods | 1 | 1988 | 1364 | 0.010 |
Why?
|
| Infant | 2 | 2015 | 35070 | 0.010 |
Why?
|
| Pattern Recognition, Automated | 1 | 2009 | 996 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2016 | 12242 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 2015 | 5095 | 0.010 |
Why?
|
| Contraceptive Devices | 1 | 2001 | 24 | 0.010 |
Why?
|
| Carcinoma, Bronchogenic | 1 | 1981 | 87 | 0.010 |
Why?
|
| Cat Diseases | 1 | 2001 | 35 | 0.010 |
Why?
|
| Bayes Theorem | 1 | 2009 | 2303 | 0.010 |
Why?
|
| Carcinogenicity Tests | 1 | 2000 | 41 | 0.010 |
Why?
|
| Odds Ratio | 1 | 1994 | 9846 | 0.010 |
Why?
|
| Toxicology | 1 | 2001 | 106 | 0.010 |
Why?
|
| Prospective Studies | 3 | 2016 | 53187 | 0.010 |
Why?
|
| Cats | 1 | 2001 | 998 | 0.010 |
Why?
|
| Random Allocation | 2 | 2000 | 2425 | 0.010 |
Why?
|
| Substance-Related Disorders | 1 | 1995 | 4250 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 15530 | 0.010 |
Why?
|
| Eye Abnormalities | 1 | 2001 | 246 | 0.010 |
Why?
|
| Risk Factors | 2 | 2017 | 72145 | 0.010 |
Why?
|
| Animals | 4 | 2004 | 168561 | 0.010 |
Why?
|
| Abnormalities, Drug-Induced | 1 | 2001 | 316 | 0.010 |
Why?
|
| Aged, 80 and over | 2 | 2015 | 57683 | 0.010 |
Why?
|
| Chlamydia Infections | 1 | 2001 | 364 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 1995 | 21719 | 0.010 |
Why?
|
| Corneal Transplantation | 1 | 2001 | 368 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 1996 | 25575 | 0.010 |
Why?
|
| Respiratory Tract Diseases | 1 | 2001 | 722 | 0.010 |
Why?
|
| Prognosis | 1 | 2016 | 29010 | 0.010 |
Why?
|
| Urinary Tract Infections | 1 | 2001 | 786 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2015 | 11472 | 0.010 |
Why?
|
| Diarrhea | 1 | 2001 | 1343 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2017 | 40450 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2009 | 14720 | 0.010 |
Why?
|
| Adult | 3 | 2015 | 213712 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2009 | 19862 | 0.010 |
Why?
|
| Colonic Neoplasms | 1 | 2001 | 2542 | 0.010 |
Why?
|
| HIV Infections | 1 | 1995 | 16678 | 0.010 |
Why?
|
| Neoplasms | 1 | 1994 | 21596 | 0.000 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 1988 | 546 | 0.000 |
Why?
|
| Rats | 1 | 2000 | 24265 | 0.000 |
Why?
|
| Anti-Bacterial Agents | 1 | 2001 | 7153 | 0.000 |
Why?
|
| Estrogens | 1 | 1988 | 1562 | 0.000 |
Why?
|
| Uterine Neoplasms | 1 | 1988 | 1513 | 0.000 |
Why?
|
| Antineoplastic Agents | 1 | 1981 | 13655 | 0.000 |
Why?
|
| Mice | 1 | 2000 | 81045 | 0.000 |
Why?
|
| Adolescent | 1 | 2001 | 85649 | 0.000 |
Why?
|
| Smoking | 1 | 1988 | 8969 | 0.000 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 1981 | 4029 | 0.000 |
Why?
|
| Adenocarcinoma | 1 | 1981 | 6347 | 0.000 |
Why?
|